Evidence map›Paper›PMID 28905027›Full record

ArticleArchives of medical sciences. Atherosclerotic diseases2016

Metabolic syndrome severity score: range and associations with cardiovascular risk factors.

Borislav D Dimitrov, Karamfil M Bahchevanov, Penka A Atanassova, Mitko D Mitkov, Radka I Massaldjieva, Kostadin A Chompalov, Georgi K Hadzhipetrov

Abstract read
In one paragraph

Article in Archives of medical sciences. Atherosclerotic diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Contribution of Components of Metabolic Syndrome to Cognitive Performance in Middle-Aged Adults.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2021
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Borislav D DimitrovPrimary Care and Population Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Karamfil M BahchevanovDepartment of Neurology, Medical Faculty, Medical University of Plovdiv, Plovdiv, Bulgaria.
Penka A AtanassovaDepartment of Neurology, Medical Faculty, Medical University of Plovdiv, Plovdiv, Bulgaria.
Mitko D MitkovDepartment of Endocrinology, Medical Faculty, Medical University of Plovdiv, Plovdiv, Bulgaria.
Radka I MassaldjievaFaculty of Public Health, Medical University of Plovdiv, Plovdiv, Bulgaria.
Kostadin A ChompalovDepartment of Neurology, Medical Faculty, Medical University of Plovdiv, Plovdiv, Bulgaria.
Georgi K HadzhipetrovDepartment of Neurology, Medical Faculty, Medical University of Plovdiv, Plovdiv, Bulgaria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMetabolic Syndrome Severity Score (MSSS) is a new clinical prediction rule (CPR) for diagnostic and therapeutic decisions and employs available components (sex, age, race, systolic blood pressure, waistline circumference, high-density lipoprotein, triglycerides and fasting blood glucose). The aim of our work was to perform cross-sectional pilot trial on middle-aged healthy volunteers and patients with metabolic syndrome (MetS) with and without type 2 diabetes mellitus (T2DM) for studying feasibility and implementation of MSSS and its associations with cardiovascular risk factors. MATERIAL AND

methodsWe approached 64 eligible participants from Bulgaria. The MSSS values, together with demographic, anthropometric, medical history, laboratory findings, CVD risk factors, QRISK2 score for 10-year cardiovascular risk and predicted heart age, were analysed. Descriptive statistics with tests for comparison (e.g.,

resultsWe analysed data from 56 participants (aged 50.11 ±3.43 years). The MSSS was higher in MetS patients (including 6 T2DM patients) than in controls (

conclusionsThe pilot study of MSSS in Bulgaria indicated feasibility and consistency of its implementation among patients with metabolic syndrome and/or T2DM and healthy volunteers.

Indexed as

metabolic syndromeriskvascular risk factors

Identifiers

PMID28905027
PMCPMC5421542

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.